A Study to Assess the Current FDA-approved AliveCor Kardia Device to Measure the QT/QTc in Patients Presenting to the Genetic Heart Rhythm Clinic

Overview

About this study

The purpose of this study is to assess the feasibility of using the current FDA-approved AliveCor Kardia device and their AliveCor Tripod device (FDA Approval pending) to measure the QT/QTc in patients presenting to the Genetic Heart Rhythm Clinic.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients age 4 -100 already scheduled to have a clinically indicated 12-lead ECG,  who are also seen in the Genetic Heart Rhythm Clinic may be included in the study. This will also include the potential to enroll age- and sex-matched patients who do not have LQTS (i.e. controls for the purpose of this study) who are also scheduled for a 12-lead ECG in either the Gonda subway, Baldwin building, or Saint Marys Hospital as part of their clinical care.
  • Family members age 4-100 without a 12-lLead ECG, who are present at the Genetic Heart Rhythm clinic without consultation.

Exclusion Criteria: 

  • Patients without the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Michael Ackerman, M.D., Ph.D.

Open for enrollment

Contact information:

Kaylie Briske

(507) 266-0470

Briske.Kaylie@mayo.edu

More information

Publications

Publications are currently not available